<DOC>
	<DOCNO>NCT01467726</DOCNO>
	<brief_summary>This Phase 1 , Randomized , Placebo−Controlled , Double−Blind , Study Safety , Pharmacokinetics Pharmacodynamics Velusetrag Healthy Elderly Subjects .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Velusetrag Healthy Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>• Is reasonably good health determine investigator base detailed medical history , full physical examination ( PE ) , vital sign ( VS ) ( include blood pressure pulse rate measurement ) , 12lead ECG , clinical laboratory test . Subjects mild , chronic , stable disease ( e.g. , control hypertension , control hypercholesterolemia , noninsulin dependent diabetes , osteoarthritis ) may enrol well control anticipate interfere objective study . Mild deviation normal limit PE , VS , ECG parameter , lab test acceptable associate stable condition agerelated Has condition , opinion investigator , would confound interfere evaluation safety tolerability PK PD investigational drug , prevent compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Elderly</keyword>
</DOC>